Far Infrared Radiation Treatment for Diabetes - Full Text View

Sponsor:	GAAD Medical Research Institute Inc.
Information provided by:	GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier:	NCT00573456

Purpose

A study to determine the use of far infrared (FIR) radiation for treatment of diabetes.

Condition	Intervention	Phase
Diabetes Mellitus	Radiation: Far Infrared Radiation	Phase I

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Diabetes

Resource links provided by NLM:

MedlinePlus related topics: Diabetes

U.S. FDA Resources

Further study details as provided by GAAD Medical Research Institute Inc.:

Primary Outcome Measures:

The primary end point is to determine the therapeutic effects of far infrared radiation on all types of diabetes. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of diabetes complications including blindness, heart and blood vessel disease and kidney failure. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Enrollment:	2
Study Start Date:	May 2006
Estimated Study Completion Date:	April 2009
Primary Completion Date:	February 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1	Radiation: Far Infrared Radiation Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.

Detailed Description:

Diabetes mellitus is a disease in which glucose is not sufficiently metabolized. This results in high glucose levels in blood and glucose in the urine. Cells can starve because glucose is not being metabolized.

Both types of diabetes can cause dangerous complications, including blindness, heart and blood vessel disease, and kidney failure. A decrease in circulation may eventually require the amputation of limbs.

We are postulating that energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to enhance the immune system; thereby improving the health of the patients.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Persons with type 1 or type 2 diabetes

Exclusion Criteria:

None

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00573456

Locations

Canada, Ontario
The Centre for Incurable Diseases
Toronto, Ontario, Canada, M4V 1L5

Sponsors and Collaborators

GAAD Medical Research Institute Inc.

Investigators

Study Director:	Ken Nedd, M.D.	GAAD Medical Research Institute Inc.
Study Chair:	Kwasi Donyina, Ph.D.	GAAD Medical Research Institute Inc.

More Information

No publications provided

Responsible Party:	GAAD Medical Research Institute Inc. ( Dr. Kwasi Donyina/Founder & President )
Study ID Numbers:	GAAD-DM-CTP1
Study First Received:	December 12, 2007
Last Updated:	August 14, 2009
ClinicalTrials.gov Identifier:	NCT00573456 History of Changes
Health Authority:	Canada: Health Canada

Keywords provided by GAAD Medical Research Institute Inc.:

Thye 1 Diabetes
Type 2 Diabetes

Additional relevant MeSH terms:

Metabolic Diseases
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on November 27, 2009